Shanghai Medicilon Inc. Stock Analysis 688202.SS

Shanghai Medicilon, Inc. engages in the preclinical comprehensive research and development services of biomedicine. The company is headquartered in Shanghai, Shanghai and currently employs 2,504 full-time employees. The company went IPO on 2019-11-05. The firm's services mainly include drug discovery, pharmaceutical research and preclinical research. Drug discovery research and development services include protein target validation, structural biology, chemical synthesis, compound activity screening and optimization. Pharmaceutical research includes active pharmaceutical ingredients and formulation process research, quality standards and stability research. Preclinical research includes pharmacodynamics, pharmacokinetics, toxicology and safety evaluation research. The firm mainly operates its businesses in the domestic and overseas markets.